Effects of Pelargonium sidoides extract vs roxithromycin on chemokine levels in nasal secretions of patients with uncomplicated acute rhinosinusitis
Članak u časopisu (Objavljena verzija)
Metapodaci
Prikaz svih podataka o dokumentuApstrakt
Background: Previous investigations suggest the use of extract from the roots of Pelargonium sidoides (EPs 7630) for the therapy of uncomplicated rhinosinusitis. The aim of this prospective study was to compare the effects of herbal drug EPs 7630 and antibiotic roxithromycin on chemokine production in nasal mucosa and clinical parameters in patients with uncomplicated acute bacterial rhinosinusitis (ABRS). Methods: Seventy-eight ABRS patients were divided into 26 patients receiving EPs 7630 tablets, 3 × 20 mg/day per os (group 1), 26 patients receiving roxithromycin tablets, 2 × 150 mg/day per os (group 2), both for 10 days, and 26 patients who received no therapy (Control group). We measured chemokine levels in nasal secretions by flow cytometry and assessed clinical parameters on day 0 and day 10 of investigation. Results: EPs 7630 increased concentrations of MCP-1 (P =.001) and IP-10 (P =.049) and decreased levels of MIP-1α (P <.001), ENA-78 (P <.001), and IL-8 (P <.001). Roxithromy...cin increased levels of IP-10 (P =.049) and decreased levels of MCP-1 (P <.001), MIP-1α (P <.016), ENA-78 (P <.001), and IL-8 (P <.001). Comparison of the non-treated patients' group with groups 1 and 2 revealed significant improvement of all clinical parameters in treated patients (P <.001), but therapy with roxithromycin resulted in better improvement in nasal symptoms and endoscopic findings than therapy with EPs 7630. Conclusion: Our results suggest the presence of similar modulatory effects of both therapies on production of chemokines that regulate the function of neutrophils and monocytes in nasal mucosa. Roxithromycin shows better clinical efficacy than EPs 7630 in patients with uncomplicated ABRS. Level of Evidence: 1b.
Ključne reči:
inflammation / antibiotic / cytokines / nasal mucosa / plants, medicinal / sinusitisIzvor:
Laryngoscope Investigative Otolaryngology, 2021, 6, 1, 25-33Izdavač:
- John Wiley and Sons Inc
Finansiranje / projekti:
- Funkcionalni, funkcionalizovani i usavršeni nano materijali (RS-MESTD-Integrated and Interdisciplinary Research (IIR or III)-45005)
DOI: 10.1002/lio2.514
ISSN: 2378-8038
WoS: 000600523200001
Scopus: 10.1002/lio2.514
Institucija/grupa
PharmacyTY - JOUR AU - Perić, Aleksandar AU - Vezmar-Kovačević, Sandra AU - Barać, Aleksandra AU - Perić, Aneta AU - Vojvodić, Danilo PY - 2021 UR - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3949 AB - Background: Previous investigations suggest the use of extract from the roots of Pelargonium sidoides (EPs 7630) for the therapy of uncomplicated rhinosinusitis. The aim of this prospective study was to compare the effects of herbal drug EPs 7630 and antibiotic roxithromycin on chemokine production in nasal mucosa and clinical parameters in patients with uncomplicated acute bacterial rhinosinusitis (ABRS). Methods: Seventy-eight ABRS patients were divided into 26 patients receiving EPs 7630 tablets, 3 × 20 mg/day per os (group 1), 26 patients receiving roxithromycin tablets, 2 × 150 mg/day per os (group 2), both for 10 days, and 26 patients who received no therapy (Control group). We measured chemokine levels in nasal secretions by flow cytometry and assessed clinical parameters on day 0 and day 10 of investigation. Results: EPs 7630 increased concentrations of MCP-1 (P =.001) and IP-10 (P =.049) and decreased levels of MIP-1α (P <.001), ENA-78 (P <.001), and IL-8 (P <.001). Roxithromycin increased levels of IP-10 (P =.049) and decreased levels of MCP-1 (P <.001), MIP-1α (P <.016), ENA-78 (P <.001), and IL-8 (P <.001). Comparison of the non-treated patients' group with groups 1 and 2 revealed significant improvement of all clinical parameters in treated patients (P <.001), but therapy with roxithromycin resulted in better improvement in nasal symptoms and endoscopic findings than therapy with EPs 7630. Conclusion: Our results suggest the presence of similar modulatory effects of both therapies on production of chemokines that regulate the function of neutrophils and monocytes in nasal mucosa. Roxithromycin shows better clinical efficacy than EPs 7630 in patients with uncomplicated ABRS. Level of Evidence: 1b. PB - John Wiley and Sons Inc T2 - Laryngoscope Investigative Otolaryngology T1 - Effects of Pelargonium sidoides extract vs roxithromycin on chemokine levels in nasal secretions of patients with uncomplicated acute rhinosinusitis VL - 6 IS - 1 SP - 25 EP - 33 DO - 10.1002/lio2.514 ER -
@article{ author = "Perić, Aleksandar and Vezmar-Kovačević, Sandra and Barać, Aleksandra and Perić, Aneta and Vojvodić, Danilo", year = "2021", abstract = "Background: Previous investigations suggest the use of extract from the roots of Pelargonium sidoides (EPs 7630) for the therapy of uncomplicated rhinosinusitis. The aim of this prospective study was to compare the effects of herbal drug EPs 7630 and antibiotic roxithromycin on chemokine production in nasal mucosa and clinical parameters in patients with uncomplicated acute bacterial rhinosinusitis (ABRS). Methods: Seventy-eight ABRS patients were divided into 26 patients receiving EPs 7630 tablets, 3 × 20 mg/day per os (group 1), 26 patients receiving roxithromycin tablets, 2 × 150 mg/day per os (group 2), both for 10 days, and 26 patients who received no therapy (Control group). We measured chemokine levels in nasal secretions by flow cytometry and assessed clinical parameters on day 0 and day 10 of investigation. Results: EPs 7630 increased concentrations of MCP-1 (P =.001) and IP-10 (P =.049) and decreased levels of MIP-1α (P <.001), ENA-78 (P <.001), and IL-8 (P <.001). Roxithromycin increased levels of IP-10 (P =.049) and decreased levels of MCP-1 (P <.001), MIP-1α (P <.016), ENA-78 (P <.001), and IL-8 (P <.001). Comparison of the non-treated patients' group with groups 1 and 2 revealed significant improvement of all clinical parameters in treated patients (P <.001), but therapy with roxithromycin resulted in better improvement in nasal symptoms and endoscopic findings than therapy with EPs 7630. Conclusion: Our results suggest the presence of similar modulatory effects of both therapies on production of chemokines that regulate the function of neutrophils and monocytes in nasal mucosa. Roxithromycin shows better clinical efficacy than EPs 7630 in patients with uncomplicated ABRS. Level of Evidence: 1b.", publisher = "John Wiley and Sons Inc", journal = "Laryngoscope Investigative Otolaryngology", title = "Effects of Pelargonium sidoides extract vs roxithromycin on chemokine levels in nasal secretions of patients with uncomplicated acute rhinosinusitis", volume = "6", number = "1", pages = "25-33", doi = "10.1002/lio2.514" }
Perić, A., Vezmar-Kovačević, S., Barać, A., Perić, A.,& Vojvodić, D.. (2021). Effects of Pelargonium sidoides extract vs roxithromycin on chemokine levels in nasal secretions of patients with uncomplicated acute rhinosinusitis. in Laryngoscope Investigative Otolaryngology John Wiley and Sons Inc., 6(1), 25-33. https://doi.org/10.1002/lio2.514
Perić A, Vezmar-Kovačević S, Barać A, Perić A, Vojvodić D. Effects of Pelargonium sidoides extract vs roxithromycin on chemokine levels in nasal secretions of patients with uncomplicated acute rhinosinusitis. in Laryngoscope Investigative Otolaryngology. 2021;6(1):25-33. doi:10.1002/lio2.514 .
Perić, Aleksandar, Vezmar-Kovačević, Sandra, Barać, Aleksandra, Perić, Aneta, Vojvodić, Danilo, "Effects of Pelargonium sidoides extract vs roxithromycin on chemokine levels in nasal secretions of patients with uncomplicated acute rhinosinusitis" in Laryngoscope Investigative Otolaryngology, 6, no. 1 (2021):25-33, https://doi.org/10.1002/lio2.514 . .